Zoetis | ZTS - Current Assets


Zoetis reported $6.47B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Align Technology USD 2.66B 38.87M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Charles River Laboratories USD 1.49B 41.76M Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Dentsply International USD 1.85B 178M Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Henry Schein USD 4.5B 32M Mar/2026
Idexx Laboratories USD 1.45B 40.25M Mar/2026
Illumina USD 2.74B 551M Mar/2026
IQVIA Holdings USD 6.22B 29M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Laboratory Of America USD 4.56B 538.3M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Neogen USD 590M 15.42M Dec/2025
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Phibro Animal Health USD 894.07M 31.88M Mar/2026
Quest Diagnostics USD 2.57B 188M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Sanofi EUR 30.95B 8.99B Dec/2025
Zoetis USD 6.47B 294M Mar/2026